Salix Pharmaceuticals, a wholly owned subsidiary of Bausch Health Companies, announced its affiliate has entered into a research agreement with Cedars-Sinai Medical Center to further investigate the microbiome in the treatment of GI disorders. Under the terms of the agreement, the lab of world-renowned microbiome researcher Mark Pimentel, M.D., executive director of the Medically Associated Science and Technology Program at Cedars-Sinai Medical Center, will focus on the discovery of new therapeutic treatments related to conditions of the gut microbiome. Dr. Pimentel has played an integral role in advancing science’s understanding of the gut microbiome including his widely-accepted research on a methanogen as an agent for causing constipation in humans. Salix has the option to acquire any therapeutic invention discovered through the research. Salix and Cedars-Sinai Medical Center are looking to begin research in the third quarter of 2018.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.